OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ICIR59

ICICI Prudential Life Insurance Company Ltd

Life & Health InsuranceVerified

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.11, indicating minimal leverage and a strong equity base. Total equity stands at INR 112.86 billion, while long-term debt is INR 12.00 billion. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. The liquidity risk is rated as medium, suggesting that while the company is not in immediate distress, it may face challenges in meeting short-term obligations without external financing. Profitability metrics show a return on equity (ROE) of 1.99% and a return on assets (ROA) of 0.07%, both of which are below the industry median for life and health insurers. This suggests that the company is underperforming in terms of capital efficiency and asset utilization compared to its peers. The operating income of INR 2.12 billion and net income of INR 2.24 billion reflect modest earnings, which may be constrained by competitive pricing pressures and regulatory costs in the Indian insurance market. The company's revenue is concentrated in India, with no material exposure to international markets. This geographic concentration increases vulnerability to domestic economic and regulatory shifts, such as changes in insurance regulations or macroeconomic downturns. The company does not disclose segment-level revenue, but as a life and health insurer, it likely operates in a single business line focused on retail insurance products. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the current or next fiscal year. The absence of a clear growth driver, such as expansion into new markets or product lines, suggests that the company is in a mature phase of its business cycle. Analysts have assigned a mean price target of INR 695.76, with a median of INR 693.50, indicating a neutral to slightly bullish outlook. The risk assessment highlights a low dilution potential, with no immediate pressure from share issuance or convertible debt. The company's diluted and basic share counts are identical, suggesting no near-term dilution from stock options or warrants. However, the risk of dilution could increase if the company issues additional shares to fund growth initiatives or refinance debt. The company has not disclosed any recent material events, such as mergers, acquisitions, or regulatory actions, that would significantly impact its operations or valuation.

30-day price · ICIR-38.35 (-6.8%)
Low$488.60High$584.75Close$522.90As of27 May, 00:00 UTC
Profile
CompanyICICI Prudential Life Insurance Company Ltd
TickerICIR.NS
SectorFinancials
BusinessInsurance
Industry groupInsurance
IndustryLife & Health Insurance
AI analysis

Business. ICICI Prudential Life Insurance Company Ltd provides life and health insurance products in India, generating revenue primarily through premium income and investment returns on its insurance reserves.

Classification. The company is classified under the Financials sector, specifically in the Insurance business sector and the Life & Health Insurance industry, with a confidence level of 0.92.

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.11, indicating minimal leverage and a strong equity base. Total equity stands at INR 112.86 billion, while long-term debt is INR 12.00 billion. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. The liquidity risk is rated as medium, suggesting that while the company is not in immediate distress, it may face challenges in meeting short-term obligations without external financing. Profitability metrics show a return on equity (ROE) of 1.99% and a return on assets (ROA) of 0.07%, both of which are below the industry median for life and health insurers. This suggests that the company is underperforming in terms of capital efficiency and asset utilization compared to its peers. The operating income of INR 2.12 billion and net income of INR 2.24 billion reflect modest earnings, which may be constrained by competitive pricing pressures and regulatory costs in the Indian insurance market. The company's revenue is concentrated in India, with no material exposure to international markets. This geographic concentration increases vulnerability to domestic economic and regulatory shifts, such as changes in insurance regulations or macroeconomic downturns. The company does not disclose segment-level revenue, but as a life and health insurer, it likely operates in a single business line focused on retail insurance products. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the current or next fiscal year. The absence of a clear growth driver, such as expansion into new markets or product lines, suggests that the company is in a mature phase of its business cycle. Analysts have assigned a mean price target of INR 695.76, with a median of INR 693.50, indicating a neutral to slightly bullish outlook. The risk assessment highlights a low dilution potential, with no immediate pressure from share issuance or convertible debt. The company's diluted and basic share counts are identical, suggesting no near-term dilution from stock options or warrants. However, the risk of dilution could increase if the company issues additional shares to fund growth initiatives or refinance debt. The company has not disclosed any recent material events, such as mergers, acquisitions, or regulatory actions, that would significantly impact its operations or valuation.
Key takeaways
  • The company maintains a low debt-to-equity ratio of 0.11, indicating a conservative capital structure.
  • Return on equity (1.99%) and return on assets (0.07%) are below industry medians, suggesting underperformance in capital efficiency.
  • Revenue is concentrated in India, increasing exposure to domestic economic and regulatory risks.
  • Analysts project a neutral to slightly bullish outlook, with a mean price target of INR 695.76.
  • The company faces medium liquidity risk due to negative net cash after subtracting total debt.
  • Dilution risk is currently low, with no immediate pressure from share issuance.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue
Gross profit
Operating income$2.12B
Net income$2.24B
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets$3.13T
Total liabilities$3.02T
Total equity$112.86B
Cash & equivalents
Long-term debt$12.00B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$9.46B$7.59B$3.50B
FY-3$13.18B$8.13B$6.25B
FY-2$5.78B$8.51B$6.41B
FY-1$15.40B$11.86B$9.74B
FY0$19.86B$16.08B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$2.44T$91.58B
FY-3$2.56T$100.90B
FY-2$2.99T$110.05B
FY-1$3.14T$119.34B
FY0$3.20T$136.31B
PeriodOCFCapExFCFSBC
FY-4$18.31B-$1.89B$3.50B
FY-3$894.9M-$1.93B$6.25B
FY-2-$73.15B-$2.37B$6.41B
FY-1-$94.13B-$2.59B$9.74B
FY0-$53.55B-$1.23B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$2.12B$2.24B
FQ-6$2.37B$2.51B
FQ-5$4.43B$3.25B
FQ-4$5.77B$3.85B
FQ-3$4.43B$3.01B
FQ-2$3.96B$2.96B
FQ-1$5.06B$3.87B
FQ0$6.41B$6.24B
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$3.13T$112.86B
FQ-6$3.27T$115.74B
FQ-5$3.14T$116.40B
FQ-4$3.14T$119.34B
FQ-3$3.28T$125.44B
FQ-2$3.25T$127.15B
FQ-1$3.34T$134.54B
FQ0$3.20T$136.31B
PeriodOCFCapExFCFSBC
FQ-7
FQ-6-$76.95B-$1.10B
FQ-5
FQ-4-$94.13B-$2.59B
FQ-3
FQ-2-$52.32B-$619.6M
FQ-1
FQ0-$53.55B-$1.23B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$112.86B
Net cash-$12.00B
Current ratio
Debt/Equity0.1
ROA0.1%
ROE2.0%
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Life & Health Insurance · cohort 15 companies
MetricICIRActivity
Op margin12.3% medp25 5.6% · p75 21.6%
Net margin2.9% medp25 0.5% · p75 10.1%
Gross margin28.2% medp25 13.4% · p75 30.5%
CapEx / revenue-2.1% medp25 -8.2% · p75 -1.2%
Debt / equity11.0%27.5% medp25 4.7% · p75 66.5%below median
Observations
IR observations
Mean price target695.76 INR
Median price target693.50 INR
High price target885.00 INR
Low price target590.00 INR
Mean recommendation1.83 (1=strong buy, 5=strong sell)
Strong-buy count13.00
Buy count15.00
Hold count7.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate11.52 INR
Last actual EPS10.94 INR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 08:52 UTC#ad77ea6c
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 04:30 UTCJob: 9c197dad